NeuroSense Therapeutics Ltd. (NRSNW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Los analistas estiman Beneficio por acción (EPS) de $-0.65 y ingresos de $0.00B para el próximo año fiscal.
Historial de Beneficio por acción (EPS): 2024: real $-0.55 vs est $-0.65 (superó +15.4%). Precisión del analista: 82%.
